Protalix Soars on FDA Approval of Gaucher Drug: Tel Aviv Mover

Protalix BioTherapeutics Inc. soared in Tel Aviv trading after the biopharmaceutical company’s first product won approval from the U.S. Food and Drug Administration.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.